We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

REAL:NASDAQThe RealReal, Inc. Analysis

Data as of 2026-04-28 - not real-time

$11.66

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Price action sits around $11.66, with the 20‑day SMA just under the 50‑day SMA and well below the 200‑day SMA, signaling a bearish backdrop. The RSI hovers in the mid‑50s and the MACD line has turned bullish against its signal, yet the overall trend direction remains bearish and the stock is trading near the $12.9 resistance while $8.05 serves as a key support. Volatility is extreme at roughly 78% over the past 30 days and beta approaches 3, reflecting heightened market sensitivity, and the historical max drawdown exceeds 50%, underscoring downside risk.
On the fundamentals side, REAL posted $693 million in revenue with an 18% growth rate and a strong 74% gross margin, but operating margins are thin and the company posted a net loss, resulting in a negative trailing EPS. Forward EPS is projected positive, yet the DCF‑derived fair value of about $3.4 is far below the current price, marking the stock as overvalued. Analysts collectively rate the stock as a strong buy, and market sentiment is in “Extreme Greed” mode, but the combination of high valuation, leverage, and sector cyclicality tempers optimism.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish technical trend with price below long‑term SMA
  • Proximity to strong support at $8.05
  • Elevated volatility and high beta

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Revenue growth of 18% and improving forward EPS
  • Analyst consensus of strong buy
  • Significant valuation gap between market price and DCF fair value

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑term secular demand for authenticated resale luxury goods
  • Positive cash flow generation and strong gross margins
  • Strategic positioning despite current overvaluation

Key Metrics & Analysis

Financial Health

Revenue Growth18.30%
Profit Margin-6.03%
P/E Ratio57.0
ROA-3.61%
P/B Ratio-3.3
Op. Cash Flow$37.0M
Free Cash Flow$24.9M

Technical Analysis

TrendBearish
RSI57.1
Support$8.05
Resistance$12.90
MA 20$10.54
MA 50$10.55
MA 200$11.19
MACDBullish
VolumeStable
Fear & Greed Index89.25

Valuation

Fair Value$3.39
Target Price$18.19
Upside/Downside55.98%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.98
Volatility78.34%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.